Blokurima
We represented the owners of Onapharm in the sale of the Blokurima product line, well known in the market for urological health products. Our goal was to find a partner that would enable the brand to grow further and expand internationally.
Our task
Patria was the exclusive sales advisor for conducting a non-public process with a narrow circle of interested parties from among pharmaceutical companies.
Patria prepared and coordinated the due diligence and negotiated the transaction documentation, including the commercial terms of the transition period.
The focus of the sales process was to maintain the high reputation of the Blokurima brand in the Czech and Slovak markets as a leader among supplements for the suppression and prevention of urinary tract inflammation symptoms.
A specific feature of this transaction was the buyer's requirement to purchase only selected assets of the company, which required the preparation of a detailed inventory management and production ordering plan during the transition period.
Results
The combination of the high-quality offerings and the reputation of the Zentiva Group was assessed as best meet the sellers' objectives, leading to a successful completion of the transaction within six months.
Onapharm Blokurima
Onapharm is a Czech manufacturer of dietary supplements with a focusing on supplements for urinary tract and genital problems. The Blokurima product line is the absolute market leader in the market for supplements for symptom control and prevention of urinary tract inflammation in the Czech Republic and Slovakia.
Zentiva Group
Zentiva is a leading pharmaceutical company in Central and Eastern Europe, focusing on the development, manufacture and distribution of generic and OTC medicines and dietary supplements. Zentiva is a portfolio company of the American investment group Advent International.